Physician profile
Anil K Singh
NPI 1114975349
$1,232.72
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.62 · 2020: $138 · 2021: $270 · 2022: $420 · 2023: $304 · 2024: $86.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $559.52 | 2020-2024 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $156.54 | 2019-2023 | Simponi Aria, Remicade, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $104.62 | 2021-2023 | Gattex, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.52 | 2020-2024 | Xifaxan |
| Vivus LLC | $68.66 | 2020-2022 | |
| Celgene Corporation | $64.06 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $46.95 | 2022-2024 | Suflave, Sutab |
| Coloplast Corp | $23.76 | 2024 | |
| Exact Sciences Corporation | $23.54 | 2023 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $22.21 | 2023 | Rebyota |
| Ardelyx, INC. | $17.49 | 2023 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $17.14 | 2022 | |
| Genzyme Corporation | $16.84 | 2022 | |
| Gilead Sciences, INC. | $16.26 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.53 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.